PREVENTION OF EVENTS WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS
使用血管紧张素转换酶抑制剂预防事件
基本信息
- 批准号:6304989
- 负责人:
- 金额:$ 0.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-12-01 至 2000-11-30
- 项目状态:已结题
- 来源:
- 关键词:cardiovascular disorder chemotherapy cardiovascular pharmacology clinical research clinical trials coronary artery coronary disorder disease /disorder proneness /risk enzyme inhibitors heart disorder chemotherapy heart function heart pharmacology heart ventricle human mortality human subject human therapy evaluation myocardial infarction peptidyl dipeptidase A
项目摘要
A clinical trial to determine if trandolapril, a drug used to treat high blood pressure and heart failure, can also prevent heart attacks and death in patients with coronary heart disease (CHD). Coronary heart disease remains a major health problem in the United States. Major strides have been made in the management of acute infarct patients with the prompt use of aspirin, beta blockers, and regimens to restore the flow of blood to an effected area of the heart, which have resulted in major reductions in in-hospital deaths. Patients who have already experienced a myocardial infarction (the death of tissue in the heart due to the lack of blood flow to that area), continue to receive benefits of contemporary therapies and greater attention directed towards modification of the known risk factors. Some treatments of risk factors are the lowering of blood pressure and cholesterol, stoppage of smoking, and changing life style. In addition, there is strong, yet unproven rationale, that ACE inhibitor therapy (angiotensin converting enzyme [a form of hormone that causes the dilation of blood vessels and the contraction of smooth muscles]) are of proven value for patients with systemic high blood pressure and for therapy for congestive heart failure. The primary goal of this study is to test whether the addition of the ACE inhibitor trandolapril will reduce the incidence of cardiovascular death or non-fatal myocardial infarction in patients with cardiovascular heart disease, but with preserved left ventrical function. The subjects of this study will be men and women 50 years and older, with CHD and the ability of their hearts to pump blood must be normal to nearly normal. Subjects cannot have abnormal kidney function, high blood pressure, high blood potassium, or be pregnant. At entry to the study, height, weight, and blood pressure will be measured. Samples of blood and urine will be collected to measure risk factors. Health and medications will be discussed and a supply of trandolapril will be given. If there is no problem with the medication, patients will then be randomly assigned to receive either trandolapril or a placebo. Return visits to the CRC will be every six months for the duration of the study for updates of records and a new supply of the medication.
一项临床试验旨在确定用于治疗高血压和心力衰竭的药物曲多普利是否也可以预防冠心病患者的心脏病发作和死亡。在美国,冠心病仍然是一个主要的健康问题。通过及时使用阿司匹林、β受体阻滞剂和恢复心脏受影响区域的血液流动的方案,在急性脑梗塞患者的治疗方面取得了重大进展,这导致了住院死亡的大幅减少。已经经历过心肌梗死(由于该区域缺乏血液而导致心脏组织死亡)的患者,继续获得当代治疗的好处,并更多地关注于修改已知的危险因素。对危险因素的一些治疗包括降低血压和胆固醇、戒烟和改变生活方式。此外,有一个强有力但未经证实的理由是,血管紧张素转换酶(血管紧张素转换酶[一种导致血管扩张和平滑肌收缩的激素])对系统性高血压患者和充血性心力衰竭的治疗具有被证明的价值。这项研究的主要目的是测试加入血管紧张素转换酶抑制剂曲多普利是否会降低心血管疾病患者的心血管死亡或非致命性心肌梗死的发生率,但这些患者的左心功能未受影响。这项研究的对象将是50岁及以上的患有冠心病的男性和女性,他们的心脏泵血能力必须正常到接近正常。受试者不能有肾功能异常、高血压、高血钾或怀孕。在进入这项研究时,将测量身高、体重和血压。将采集血液和尿液样本以衡量危险因素。将讨论健康和药物,并将提供曲多普利。如果药物治疗没有问题,患者将被随机分配接受曲多普利或安慰剂。在研究期间,将每六个月对儿童权利委员会进行一次回访,以更新记录和提供新的药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GEORGE W. VETROVEC其他文献
GEORGE W. VETROVEC的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GEORGE W. VETROVEC', 18)}}的其他基金
Prevention of Events with Angiotensin Converting Enzyme Inhibition
通过抑制血管紧张素转换酶来预防事件
- 批准号:
7040914 - 财政年份:2003
- 资助金额:
$ 0.06万 - 项目类别:
ANTIHYPERTENSIVE AND LIPID LOWERING TREATMENT TO PREVENT HEART ATTACK
抗高血压和降脂治疗预防心脏病
- 批准号:
6304984 - 财政年份:1999
- 资助金额:
$ 0.06万 - 项目类别:
ANTIHYPERTENSIVE AND LIPID LOWERING TREATMENT TO PREVENT HEART ATTACK
抗高血压和降脂治疗预防心脏病
- 批准号:
6218487 - 财政年份:1998
- 资助金额:
$ 0.06万 - 项目类别:
ANTIHYPERTENSIVE AND LIPID LOWERING TREATMENT TO PREVENT HEART ATTACK
抗高血压和降脂治疗预防心脏病
- 批准号:
6114894 - 财政年份:1998
- 资助金额:
$ 0.06万 - 项目类别:
PREVENTION OF EVENTS WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS
使用血管紧张素转换酶抑制剂预防事件
- 批准号:
6114904 - 财政年份:1998
- 资助金额:
$ 0.06万 - 项目类别:
PREVENTION OF EVENTS WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS
使用血管紧张素转换酶抑制剂预防事件
- 批准号:
6218497 - 财政年份:1998
- 资助金额:
$ 0.06万 - 项目类别:
PREVENTION OF EVENTS WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS
使用血管紧张素转换酶抑制剂预防事件
- 批准号:
6276139 - 财政年份:1997
- 资助金额:
$ 0.06万 - 项目类别:
ANTIHYPERTENSIVE AND LIPID LOWERING TREATMENT TO PREVENT HEART ATTACK
抗高血压和降脂治疗预防心脏病
- 批准号:
6246029 - 财政年份:1997
- 资助金额:
$ 0.06万 - 项目类别:
ANTIHYPERTENSIVE AND LIPID LOWERING TREATMENT TO PREVENT HEART ATTACK
抗高血压和降脂治疗预防心脏病
- 批准号:
6276129 - 财政年份:1997
- 资助金额:
$ 0.06万 - 项目类别:
相似海外基金
Cardiovascular pharmacology of the B1 and B2 receptors for kinins
激肽 B1 和 B2 受体的心血管药理学
- 批准号:
170936 - 财政年份:2008
- 资助金额:
$ 0.06万 - 项目类别:
Operating Grants